ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Bristol-Myers Squibb will give Nektar Therapeutics $1.85 billion up front and potentially another $1.78 billion to jointly develop Nektar’s protein-based cancer immunotherapy NKTR-214. BMS is betting on combining NKTR-214, currently in a Phase I/II trial, with its two approved antibody checkpoint inhibitors, Opdivo and Yervoy. Trials are planned for nine tumor types. NKTR-214 is a prodrug of the immune-system-activating cytokine interleukin-2, already a cancer treatment. The drug binds the interleukin-2 receptor, leading to stimulated immune cells that target tumors.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X